Media Centre
Latest press releases
-
AstraZeneca advances the science of infectious disease protection at ECCMID 2024
-
Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
-
New modelling reveals the escalating toll of chronic kidney disease on patients, planet and economies
-
AstraZeneca increases 2024 dividend by 7%
-
Alexion data at AAN 2024 demonstrate how Ultomiris and Soliris can transform outcomes for rare neurological diseases
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.